Dual Obstructive Sleep Apnea Therapy
Dual Obstructive Sleep Apnea Therapy
Continuous positive airway pressure (CPAP) is considered the gold standard therapy for
 obstructive sleep apnea (OSA). However, CPAP users sometimes experience pressure-related
 discomfort. It is thought that lower CPAP pressure may increase comfort and lead to greater
 treatment adherence.

 Mandibular advancement splint (MAS) therapy has been shown to be the preferred OSA treatment
 option among patients. However, MAS therapy is only partially effective in some OSA patients,
 especially in severe cases.

 It is thought that a combination of MAS and PAP therapy may benefit patients in which MAS
 alone is only partially effective. Using MAS and PAP at the same time is called "Dual
 Therapy". Dual Therapy may allow a lower CPAP pressure to be applied, which may increase
 patient comfort and therefore increase treatment adherence and overall effectiveness.

 This study will evaluate the effectiveness of 1 month of Dual Therapy in 30 OSA patients.
This is a prospective clinical trial assessing the effect of 1-month of dual therapy on
 patients with varying baseline OSA severity (mild to severe) who have been previously fully
 titrated to both PAP and MAS.

 This study will be conducted at 2 research centers; the Faculty of Dentistry, University of
 British Columbia (UBC), Vancouver and at the Faculty of Dentistry, Université de Montréal
 (UdM), Montréal.

 The research team will access participants' records to confirm eligibility for dual therapy.
 The clinical research coordinator will contact eligible patients via phone to ask if they are
 interested in taking part in the study. Eligible patients will also be asked if they are
 interested in taking part in the study during routine clinic visits. Where possible, patients
 will not be approached by their primary caregiver regarding participation in this study, to
 ensure patients do not feel pressurized into participating. Choosing not to take part in the
 study will not affect the participants' quality of care. If a patient is interested in taking
 part in the study they will be invited to review and sign the informed consent form.

 Consenting participants will be asked to use both MAS and PAP (dual therapy) together for a
 period of 1 month. During the first week of the dual therapy, PAP pressure will be adjusted
 automatically for a 1-week period, after which the pressure will be set remotely by the
 Respiratory Therapist at the 90th percentile.

 With permission, the research team will access the Sleep Apnea Dental Clinic records to
 collect data relating to previous treatment with MAS and PAP monotherapies. Data collected
 includes: PAP pressure, treatment adherence, subjective treatment assessment, Epworth
 Sleepiness Scale (ESS) and Functional Outcomes of Sleep Questionnaires (FOSQ), weight, blood
 pressure and oximetry data.

 At the end of the 1-month, a subjective and objective assessment will be conducted.
 Subjective data will be collected using a short questionnaire that will be completed by the
 participants pertaining to their experience with the dual therapy in addition to completing a
 short term medical/treatment update form. Participants' weight and blood pressure will also
 be reassessed. Objective adherence will be analyzed via data obtained from the PAP modem and
 from DentiTrac® smart chips embedded in the MAS. OSA-related quality of life will be
 reassessed using ESS and FOSQ questionnaires.
Inclusion Criteria:

 -  Age 19-80 years old who are able to freely provide informed consent;

 -  Prior participation in the CHOICE study;

 -  Have been optimally titrated to PAP and MAS therapy;

 -  Have both PAP and MAS appliances at home and ready for use;

 -  Body mass index (BMI) of 35 or less;

 -  ≥ 8 teeth per arch to support treatment with MAS;

 -  Have an objective of diagnosis of OSA based on the following criteria:

 -  - an Apnea-Hypopnea Index (AHI) within the range 10 ≤ AHI ≤ 70 documented with
 polysomnography in the last 2 years; ***OR***

 -  - a Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 70 documented with
 level III portable sleep test; ***OR***

 -  - an Oxygen Desaturation Index (ODI) ≥ 10;

 -  Sleep investigations confirming the object diagnosis of OSA have been performed within
 the past 4 years

 Exclusion Criteria:

 -  Use of a full face mask as the PAP interface;

 -  Extensive periodontal disease with significant tooth mobility;

 -  Inability to protrude jaw;

 -  Insufficient vertical opening to accommodate treatment with MAS;

 -  Uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an
 ejection cut-off of 40% or clinical sign in the opinion of a primary care physician or
 cardiologist) that makes it unsafe in the opinion of the investigators for the subject
 to participate in the trial;

 -  Coronary artery disease unless stable for at least 6 months and considered by the
 investigators to have a stable disease;

 -  Any history of angina, myocardial infarction or stroke;

 -  Any history of major depressive disorder along with current moderate-severe disease;

 -  Active cancer management (unless in remission for more than 1 year);

 -  Known renal failure (with need for dialysis);

 -  History of a near miss or prior automobile accident due to sleepiness within the past
 12 months;

 -  At nighttime, 30% of the night is at ≤ 90% oxygen saturation levels.